It has been calculated that it is cost beneficial to screen for C trachomatis when the prevalence of genital chlamydial infection is approximately 6%6 and when treating all detected cases with 1 g of azithromycin as a single dose (assuming a non-existent compliance problem if the drug is given at a clinic). In another study8, which used different criteria for diagnosing PID, included an estimate of the number of silent PIDs, and used other methods for detecting chlamydia infection, a prevalence of 3% was found to be the cut off for screening shown to be cost beneficial.
In 24 family planning clinics in 14 European countries, we found the prevalence of C trachomatis infections in 3000 women aged 15 to 45 years, who considered themselves to be gynaecologically healthy, to range from 00% to 7.6%.2 The study made use of a PCR method for testing urine samples. In five of these countries, the prevalences were above 3%. Selective screening is likely to increase the cost-benefit rates in populations with overall prevalences below the threshold for gain. Thus, screening of cohorts of women with known risk factors for infection or symptomatic cases-for example, women complaining of vaginal discharge, is likely to identify even higher prevalences than in asymptomatic cohorts. Furthermore, if partner notification is undertaken among the sexual partner(s) of individuals found positive at screening and also of the partner's partner(s), such case detection is likely to increase the cost-benefit further.
Which methods should be used for screening? The method used must be suitable for its purpose-that is, the right method for the right type of sample for a given person or population being examined. In mass screening it is important that the method will allow non-invasive sampling. Nucleic acid based methods must be recommended if economy allows.6710 LCR or PCR can be used for urethral/cervical samples, for voided urine samples," 12 and also for vaginal introital specimens"; the latter with the same or ever higher sensitivity than when analysing any other type of sample by the same methodology.
The advantage of using a PCR or LCR method is that these methods allow simultaneous detection of more than one STD agentfor example, diagnosis of a genital chlamydial infection and gonorrhoea by testing the same urine sample. In the future it seems likely that a whole battery of primers of sexually transmittable agents may be used, which will increase the motivation to introduce STD screening programmes. Screening in certain age groups for oncogenic types of human papillomavirus (HPV) are among top candidates for such an initiative. '4 In eastern Europe tests for syphilis are becoming another top priority for STD screening programmes, although this will require blood to be drawn for serological tests. Such tests for HPV antibodies may also be informative." ' The use of PCR and LCR has increased the percentage of infected people detected, compared with previously used methods, such as DIF (direct immunofluorescence) and ELISA. The exact increase in sensitivity achieved by introducing these new methods is speculative, but for C trachomatis has ranged from 10% to at least 50% depending on sample type and test population studied. Another factor is the performance quality of earlier methods used, such as that of tissue cell culture for detection of chlamydiae. When testing cases of chronic chlamydial infections in which the chlamydia antigen load may be very low, the use of DNAIRNA based methods is even more essential. Nucleic amplification methods are not without their problems, however.'6 17 A low antigen load may be more common among women in their thirties with chronic long standing chlamydial infections than among female teenagers with acute primary infections. We found little variation by age in the prevalence of chlamydia positive cases in the European screening study of family planning attendees aged 18-45 years referred to above, in which we used a PCR test.9 Our study indicated that focusing only on older teenagers and women in their twenties in screening programmes for C trachomatis is not likely to be an optimal approach if one aims to obtain a maximum health gain-that is, a maximum number of case detected, treated, and thus the prevention of the spread of the infection to non-infected individuals. However, the cost-benefit of such extended screening programmes remains to be determined in attempts to reduce the reservoir of the organism in the general European female population.
Which method one should use for screening for genital chlamydial infection also depends on the type of sample available-for example, a voided urine sample or a cervical swab and what techniques are available in the local laboratory as well as the prevailing conditions for storage and transport of samples. One essential question for sampling is that of whether the specimen to be tested is to be collected at a clinic with a gynaecological examination chair available. So far, almost all epidemiological data on genital chlamydial infections in females have been restricted to populations with this test prerequisite. Also, the extent to which existing laboratory equipment can be adapted to new methods and the experience of the laboratory staff can 
